Liestal

Researchers are evaluating the effectiveness, safety, and tolerability of camizestrant combined with ribociclib in patients with advanced ER-positive, HER2-negative breast cancer who have not received any prior systemic treatment for their advanced disease. This Phase IIIb global, multicenter, single-arm study aims to provide insight into this combination therapy as a first-line treatment option. Participants will receive daily oral tablets of camizestrant 75 mg and ribociclib 600 mg at standard doses continuously until they choose to stop treatment or it is discontinued for any reason. Approximately 150 participants will be enrolled and treated within this trial. During the study, participants will be monitored for treatment effectiveness using time to next treatment, time to discontinuation, and progression-free survival over a two-year period. Safety will be assessed by tracking adverse events, including any severe toxicities within the first six months. Participants will undergo regular assessments related to organ function and performance status throughout the treatment period, which may last until discontinuation.

Researchers are evaluating elacestrant compared to standard endocrine therapies in adults with node-positive, Estrogen Receptor-positive ER, HER2-negative early breast cancer who are at high risk of cancer returning. The study focuses on those who have had prior endocrine therapy and aims to measure how well elacestrant may prevent invasive breast cancer recurrence over five years. Participants are randomly assigned to receive either 345 mg of elacestrant daily for five years or continue their prior standard endocrine therapy, which may include an aromatase inhibitor anastrozole, letrozole, or exemestane or tamoxifen. The trial is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will have regular assessments to monitor cancer recurrence, survival, side effects, and quality of life. Evaluations include questionnaires on health status and physical functioning at baseline, six months, and annually for up to five years. Safety is tracked through adverse event reporting up to five years plus 28 days. The total participation duration can last up to five years with ongoing monitoring and data collection.

This study evaluates the long-term safety and tolerability of pelacarsen TQJ230 in people with established cardiovascular disease and elevated Lipoproteina who completed a previous related study. It is an open-label extension trial, meaning all participants receive the study drug without placebo comparison. The trial is sponsored by Novartis Pharmaceuticals and focuses on continued treatment after the completion of the parent study. Participants receive monthly injections of pelacarsen 80 mg subcutaneously for up to 36 months during this extension phase. This phase is designed to provide access to the study drug after the initial trial and to monitor participants closely. The study does not involve randomization or blinding, and all enrolled participants receive the active drug. During the study, participants will undergo regular assessments including monitoring for adverse events and cardiovascular events, as well as measuring Lipoproteina levels at baseline and several time points over 36 months. Safety and tolerability will be closely tracked throughout the treatment period. The total duration of participation corresponds to the length of the extension phase, up to three years.

Researchers are studying circulating tumor cells CTCs and clusters of CTCs in various types of cancer to better understand their biology and role during disease progression. This observational study aims to evaluate CTCs as biomarkers and identify key signaling networks active in these cells, involving patients with different solid tumor cancers. The study is led by the University Hospital in Basel, Switzerland, and covers a wide range of cancer stages and subtypes. Participants will provide blood samples, typically collected in tubes containing EDTA, for isolation and detailed analysis of CTCs. For those undergoing tumor resection, additional samples will be taken from tumor draining vessels. These samples will undergo molecular analysis, culture, and drug screening to explore characteristics of the CTCs. The study does not involve any treatments but focuses on collecting and analyzing these biological samples over time. Participants will be followed for an extended period, up to around 20 years, with evaluations including overall survival and progression-free survival. The total number of isolated CTCs will also be monitored throughout the study. The long-term observation allows researchers to study changes in CTCs over disease progression. Participants will provide informed consent and undergo regular blood sampling, with no interventions beyond sample collection.

Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.

Researchers are investigating the use of Trastuzumab deruxtecan T-DXd in adults with unresectable or metastatic HER2-low and HER2-ultralow breast cancer. This includes patients who have previously received chemotherapy for metastatic breast cancer or have hormone receptor-positive disease treated with endocrine therapy but are unsuitable for further endocrine treatment. The study aims to understand treatment effectiveness, patient characteristics, and experiences in a real-world setting through a non-interventional approach. Participants will be observed while receiving either T-DXd or conventional chemotherapy as part of their routine care, without any drug administration by the study itself. The study includes two groups one with patients having HER2-low breast cancer treated with T-DXd after prior chemotherapy, and another with hormone receptor-positive, HER2-low or HER2-ultralow breast cancer patients treated with either T-DXd or conventional chemotherapy but not prior chemotherapy for metastatic disease. Data will be collected on treatments, side effects, and management of adverse drug reactions. During the study, participants demographic and clinical data, treatment patterns, tolerability, and quality of life will be monitored over approximately 37 months. Assessments include the time to next treatment, treatment discontinuation, physician-reported safety events, patient-reported tolerability, quality of life questionnaires, and symptom diaries. This long-term observation will help evaluate real-world outcomes and patient experiences with T-DXd and conventional chemotherapy in this population.

Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd combined with either rilvegostomig or pembrolizumab compared to standard chemotherapy with carboplatin and paclitaxel plus pembrolizumab in treating women with HER2-expressing, mismatch repair proficient pMMR, advanced or recurrent endometrial cancer. This Phase III study focuses on progression-free survival PFS as the main measure of treatment success. Participants are randomly assigned to one of three groups Arm A receives T-DXd and rilvegostomig intravenously every three weeks Arm B receives T-DXd and pembrolizumab intravenously every three weeks Arm C receives carboplatin and paclitaxel intravenously every three weeks for six cycles plus pembrolizumab every three weeks, followed by pembrolizumab maintenance every six weeks for up to 20 total cycles or about 24 months. Docetaxel may replace paclitaxel if needed. Treatment continues until disease progression or other reasons to stop treatment. During the study, participants undergo regular assessments including imaging and laboratory tests to monitor disease status and treatment effects. Researchers will evaluate progression-free survival until disease progression or death, overall survival, response rates, safety, pharmacokinetics, and patient-reported tolerability over periods ranging up to approximately 70 months. Safety monitoring continues for 90 days after the last dose. The study aims to better understand treatment options for this type of endometrial cancer.

Researchers are evaluating whether digital voice analysis can identify measurable changes in audio signals that reflect frailty and emotional distress in patients with cancer. Frailty, a common syndrome especially among older adults, increases risks such as falls, disability, hospitalization, and death. Detecting frailty and distress early is important for improving patient care and treatment outcomes. This study will gather voice recordings alongside conventional assessments to explore the potential relationship between voice features and patient wellbeing over time. Participants will use a tablet to describe images freely while their speech is recorded with synchronized audio and video. These recordings will be analyzed for various voice parameters like frequency, voice quality, and fluency. Alongside voice data, participants will complete the G8 questionnaire to assess frailty and the Distress Thermometer to measure psychological distress. The study includes two groups of cancer patients from a palliative care center and a mid-size cancer center, with multiple recording sessions over several weeks. Participants will be followed for up to 16 weeks, during which changes in specific voice features such as fundamental frequency, jitter, shimmer, voice strength, and speech duration will be tracked and compared to clinical assessments. The study aims to conduct detailed analyses of how voice characteristics vary with frailty and distress both between different patients and within the same patient over time. Data collection includes clinical evaluations and questionnaires, with researchers monitoring these changes to identify potential markers for future larger studies.

Researchers are observing the long-term outcomes and adherence of the Inspire UAS System, a device used for patients with obstructive sleep apnea OSA. This observational registry aims to track the patients experience with the Inspire System through regular clinical care visits, capturing data throughout the patients use of the device. The study is sponsored by Inspire Medical Systems, Inc. and does not require any additional interventions or testing beyond routine care. Participants in this study will have the Inspire UAS System implanted, which includes three components an implantable pulse generator, a stimulation lead, and a sensing lead. Patients also receive a remote control to activate the therapy. The registry collects data during routine follow-up visits and does not involve experimental treatments or randomization. Throughout the study, participants will have clinical data collected such as the Apnea Hypopnea Index AHI, Epworth Sleepiness Scale ESS, and other sleep-related assessments if available from routine care. Researchers will monitor therapy use, patient experience, and any adverse events reported during implant and follow-up visits. The study will continue through April 2035, allowing long-term observation of the Inspire Systems use in everyday clinical settings.

This research aims to determine whether performing an extended pelvic lymph node dissection ePLND during radical prostatectomy benefits men with high-risk prostate cancer. The study investigates if ePLND improves cancer staging and removes undetectable cancer cells that standard imaging techniques like PSMA-PET might miss, potentially leading to better treatment outcomes. The trial is a multicenter, randomized phase III study sponsored by University Hospital, Basel, Switzerland. Participants will be randomly assigned to one of two groups radical prostatectomy with extended pelvic lymph node dissection or radical prostatectomy without the extended lymph node dissection. Extended PLND involves removing more lymph nodes than the standard procedure, aiming for better detection of cancer spread. The study compares outcomes between these two approaches, while considering surgery time and complication risks, which may be slightly higher with ePLND. During the study, participants will be monitored over a long-term period of up to 10 to 15 years. Researchers will measure prostate-specific antigen PSA persistence about 3 months after surgery and track biochemical recurrence-free survival within 24 months. Secondary measures include time to recurrence, metastasis, survival rates, complications, adverse events related to ePLND, and patient-reported outcomes. This comprehensive follow-up includes assessments during surgery, postoperatively, and over many years to evaluate the overall impact of the surgical approaches.